Team 58: Clinical Research Groups (GRC) ONCOTYPE-URO

Prostate cancer (PC) is the most common cancer in men, with approximately 8,800 deaths per year in France. The metastatic phase of the disease, leading to death, remains poorly controlled by existing treatments. In this context, the aim of this project is to identify, at an early stage, the landscape of mutations and/or chromosomal alterations leading to the progression to metastatic disease. To this end, this pilot study is initially based on the analysis of a sample of metastatic lymph nodes from patients with prostate cancer. The full genome and transcriptome sequencing planned for the DNA and RNA extracted from this metastatic tissue will allow the characterization of chromosomal alterations present in the metastatic stage of CP, compared to the germline DNA of the same patient used as a reference. This project will also study the multifocality and tumour heterogeneity of prostate cancer by comparing the DNA profile of the entire genome of three different foci of prostate tumour tissue from the same CP case. Indeed, many studies have shown that 60-90% of prostate cancers are multifocal at the time of diagnosis but, in reality, the biological basis of this multifocality and histological heterogeneity attributed to prostate cancer has not been fully elucidated. We will also be able to compare the pattern of chromosomal alterations identified during this study with those found during the French ICGC prostate cancer program on aggressive cases, coordinated by our team.   Website: https://medecine.sorbonne-universite.fr/recherche/groupes-de-recherche-clinique/grc-5-oncotypeuro/ Affiliations: UPMC/GRC ONCOTYPE-URO Contact: olivier.cussenot@aphp.fr

• 
• 
• 
• 
•